Wu Min, Shen Lin
Department of Hematology, Huadong Hospital, Fudan University, No.221, Yan 'an West Road, Jing' an District, Shanghai, 200040, China.
World J Surg Oncol. 2024 Dec 18;22(1):330. doi: 10.1186/s12957-024-03613-0.
BACKGROUND/AIM: This research study was conducted to examine the clinical characteristics and post-splenectomy survival outcomes of patients diagnosed with hepatosplenic T-cell lymphoma (HSTCL).
A total of 10 cases of HSTCL patients admitted to the Hematology Department of Fudan University Affiliated Huadong Hospital between January 2012 and December 2021 were included. In addition, we also included 30 other cases reported from domestic and international sources. All pathological specimens were stained with hematoxylin and eosin (H&E) and immunohistochemistry, with color development using DAB staining. Survival analysis was conducted using Kaplan-Meier curves and log-rank tests.
In the 10 HSTCL patients, Epstein-Barr virus (EBV) infection was confirmed. Six patients had died, with 5 of them within 1 year of disease onset. Survival analysis showed poorer prognosis in patients with hemophagocytic syndrome and thrombocytopenia. Patients who underwent splenectomy followed by chemotherapy had a higher median and average survival time compared to those who only received chemotherapy. The study included a total of 40 HSTCL patients, with 29 males and 11 females, and an average age of onset at 42.3 years. All patients presented with fever, with some exhibiting emaciation and/or hemophagocytic syndrome. Splenomegaly, hepatomegaly, lymphadenopathy, and bone marrow involvement were found in the patients. Common laboratory findings included leukopenia, anemia, and thrombocytopenia. All patients exhibited elevated ferritin levels and decreased blood calcium levels.
Those patients suffering from hemophagocytic syndrome at the onset of this disease face greater treatment-related difficulties and a higher risk of mortality. Combined chemotherapy after splenectomy may improve HSTCL patient survival.
背景/目的：本研究旨在探讨诊断为肝脾T细胞淋巴瘤（HSTCL）患者的临床特征及脾切除术后的生存结局。
纳入2012年1月至2021年12月复旦大学附属华东医院血液科收治的10例HSTCL患者。此外，还纳入了国内外报道的其他30例病例。所有病理标本均进行苏木精-伊红（H&E）染色和免疫组化，采用DAB染色显色。采用Kaplan-Meier曲线和对数秩检验进行生存分析。
10例HSTCL患者中确诊为EB病毒（EBV）感染。6例患者死亡，其中5例在疾病发病1年内死亡。生存分析显示，噬血细胞综合征和血小板减少症患者预后较差。与仅接受化疗的患者相比，接受脾切除术后化疗的患者中位生存时间和平均生存时间更高。该研究共纳入40例HSTCL患者，其中男性29例，女性11例，平均发病年龄为42.3岁。所有患者均有发热，部分患者有消瘦和/或噬血细胞综合征表现。患者出现脾肿大、肝肿大、淋巴结肿大和骨髓受累。常见实验室检查结果包括白细胞减少、贫血和血小板减少。所有患者铁蛋白水平升高，血钙水平降低。
本病发病时患有噬血细胞综合征的患者面临更大的治疗相关困难和更高的死亡风险。脾切除术后联合化疗可能改善HSTCL患者的生存。
